Business
PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership
PreciseDx, the leading innovator behind PreciseBreast, a novel breast cancer diagnostic that is powered by OncoIntelligence, their proprietary AI-platform, today announced the successful closing of $11 million in funding and two key leadership hires. This latest round of funding was led by Eventide Asset Management ("Eventide"), Merck Global Health Innovation Fund and Philips Ventures and included Labcorp, Quest Diagnostics, GenHenn Capital Venture, along with other existing investors. This fund
About this update from Labcorp Holdings Inc.
[{"type":"text","content":"Funding now totals over $43 million, strengthened leadership focused on a 2026 commercial launch of the OncoIntelligence™-driven, PreciseBreast™","length":149,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, June 18, 2025 /PRNewswire/ -- PreciseDx, the leading innovator behind PreciseBreast, a novel breast cancer diagnostic that is powered by OncoIntelligence, their proprietary AI-platform, today announced the successful closing of $11 million in funding and two key leadership hires. This latest round of funding was led by Eventide Asset Management ("Eventide"), Merck Global Health Innovation Fund and Philips Ventures and included Labcorp, Quest Diagnostics, GenHenn Capital Venture, along with other existing investors. This funding will help prioritize the company's ongoing clinical data collection, commercial expansion and planning for the 2026 launch of its flagship product, PreciseBreast.","length":720,"tagName":"p"},{"type":"image","alt":"https://precisedx.ai/ (PRNewsfoto/PreciseDx)","displaySize":"","headline":null,"caption":"https://precisedx.ai/ (PRNewsfoto/PreciseDx)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":45,"url":"https://media.zenfs.com/en/prnewswire.com/9cec807d8f8e157a17950cad389d77af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3TM2wqY.bdwktMM6ZQ0E0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTc5O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/9cec807d8f8e157a17950cad389d77af","width":400,"height":45}},"href":"https://mma.prnewswire.com/media/1723476/PreciseDx_logo1_CMYK_210311_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The news also comes as the company announces two critical leadership appointments. Eric Converse, a seasoned leader with imaging diagnostics and AI/ML technologies experience has assumed the role of Chief Executive Officer. Additionally, Ed Sitar, who has over 30 years of financial leadership in diagnostics and market access, has become the Chief Financial Officer.","length":367,"tagName":"p"},{"type":"text","content":""This represents a defining moment for PreciseDx and our mission to support physicians and patients in making more informed, biologically driven decisions in the management of breast cancer," said Founder Carlos Cordon-Cardo, MD, PhD, Professor and System Cha...